Nausea News and Research RSS Feed - Nausea News and Research

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.
Rome IV criteria helps diagnose, treat gastrointestinal conditions in children

Rome IV criteria helps diagnose, treat gastrointestinal conditions in children

A child feels nauseated all the time, but no medical test can find what is wrong. Or a child vomits regularly, but there's no illness or eating disorder to explain it. These, and other stomach and bowel-related problems with no obvious causes, are called functional gastrointestinal disorders. [More]
Patients undergoing breast cancer surgery with non-opiate anaesthesia may need less painkillers

Patients undergoing breast cancer surgery with non-opiate anaesthesia may need less painkillers

New research presented at Euroanaesthesia 2016 shows that patients undergoing breast cancer surgery need less painkilling medication post-surgery if they have anaesthesia that is free of opioid drugs. [More]
First buprenorphine implant for opioid dependence treatment gets FDA approval

First buprenorphine implant for opioid dependence treatment gets FDA approval

The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program. [More]
Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial. [More]
Tecentriq drug gets FDA approval to treat urothelial carcinoma

Tecentriq drug gets FDA approval to treat urothelial carcinoma

The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer. [More]
Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion. [More]
Magic mushroom compound may offer potential new way for antidepressant research

Magic mushroom compound may offer potential new way for antidepressant research

Psilocybin – a hallucinogenic compound derived from magic mushrooms – may offer a possible new avenue for antidepressant research, according to a new study published in The Lancet Psychiatry today. [More]
Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Neos Therapeutics, Inc., a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Adzenys XR-ODT™ is in distribution channels and is now available to prescribe for patients with ADHD in the United States. [More]
Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF). [More]
International study shows direct link between continued marijuana use during pregnancy and pre-term birth

International study shows direct link between continued marijuana use during pregnancy and pre-term birth

International research led by the University of Adelaide has for the first time shown a direct link between continued marijuana use during pregnancy and pre-term birth. [More]
UCLA study shows anti-nausea drug does not increase risk of birth defects

UCLA study shows anti-nausea drug does not increase risk of birth defects

Women suffering from extreme morning sickness often take Zofran (ondansetron) to combat their debilitating nausea and vomiting. However, two studies have found that the drug may increase risk of heart defects and cleft palate in children exposed in utero. [More]
Common misconception about penicillin allergies

Common misconception about penicillin allergies

It's time for your primary care check-up, and the doctor asks you to list any known drug allergies. "Penicillin," you say immediately, although you can't remember actually taking the drug or having a reaction to it—it was your parents who said so. According to a Texas A&M Health Science Center allergist, many people who believe they're allergic to this antibiotic may not actually be allergic at all. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Flu vaccinations for pregnant women reduce newborn’s influenza risk during first six months of life

Flu vaccinations for pregnant women reduce newborn’s influenza risk during first six months of life

Babies whose moms get flu vaccinations while pregnant have a significantly reduced risk of acquiring influenza during their first six months of life, a new study shows, leading the authors to declare that the need for getting more pregnant women immunized is a public health priority. [More]
Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions

Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions

The U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson's disease. [More]
First generic version of Crestor gets FDA approval

First generic version of Crestor gets FDA approval

The U.S. Food and Drug Administration today approved the first generic version of Crestor (rosuvastatin calcium) tablets. [More]
Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Janssen-Cilag International NV today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a Positive Opinion, recommending broadening the existing marketing authorisation for ibrutinib as a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). [More]
Research highlights global economic burden of norovirus

Research highlights global economic burden of norovirus

While norovirus is often linked in the news to outbreaks on cruise ships, the highly contagious stomach bug sickens nearly 700 million around the world every year and results in roughly $4.2 billion in health care costs and $60.3 billion in societal costs annually, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]
Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet. [More]
Study aims to determine how aches, pains before and after concussion play role in recovery

Study aims to determine how aches, pains before and after concussion play role in recovery

Athletes who have medical complaints, like aches and pains, that have no known physical cause may take longer to recover after a concussion, according to a study published in the April 20, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Advertisement